B. Metzler seel. Sohn & Co. AG Grows Stake in Repligen Corporation $RGEN

Key Points

• B. Metzler seel. Sohn & Co. AG increased its Repligen stake by 52.8% in the second quarter, bringing its holdings to 26,361 shares valued at approximately $3.6 million. Institutional investors collectively own 97.64% of the company.
• Repligen exceeded quarterly expectations, reporting $0.54 in EPS versus the $0.45 consensus and revenue of $204.13 million, up 11.9% year over year. The company reaffirmed fiscal 2026 EPS guidance of $2.03–$2.09.
• Analyst sentiment remains favorable, with a consensus “Buy” rating and an average price target of $166.43, although CFO Jason Garland sold 733 shares and the stock was recently trading at $167.60.

B. Metzler seel. Sohn & Co. AG lifted its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 52.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,361 shares of the biotechnology company's stock after acquiring an additional 9,108 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Repligen were worth $3,597,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. NewEdge Wealth LLC lifted its holdings in Repligen by 5.3% during the fourth quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company's stock worth $244,000 after buying an additional 75 shares during the period. UMB Bank n.a. increased its holdings in shares of Repligen by 13.8% in the 4th quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company's stock valued at $124,000 after acquiring an additional 92 shares during the period. CANADA LIFE ASSURANCE Co raised its position in shares of Repligen by 0.3% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company's stock worth $4,542,000 after acquiring an additional 100 shares in the last quarter. Coldstream Capital Management Inc. raised its position in shares of Repligen by 5.3% in the 4th quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company's stock worth $326,000 after acquiring an additional 101 shares in the last quarter. Finally, Itau Unibanco Holding S.A. lifted its stake in shares of Repligen by 38.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company's stock worth $62,000 after purchasing an additional 104 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Insider Transactions at Repligen

In other Repligen news, CFO Jason Garland sold 733 shares of the company's stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.60% of the company's stock.

Repligen Stock Down 1.2%

NASDAQ:RGEN opened at $167.60 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The company's fifty day moving average price is $155.54 and its 200-day moving average price is $134.25. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $188.73. The firm has a market capitalization of $9.46 billion, a P/E ratio of 229.59, a PEG ratio of 3.10 and a beta of 1.05.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.09. The company had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities research analysts anticipate that Repligen Corporation will post 2.06 EPS for the current year.

Analyst Upgrades and Downgrades

RGEN has been the topic of a number of recent research reports. Wolfe Research assumed coverage on Repligen in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $145.00 price objective on the stock. Benchmark upgraded shares of Repligen from a "hold" rating to a "buy" rating and set a $185.00 target price for the company in a report on Tuesday, July 7th. Evercore reissued an "outperform" rating and set a $160.00 price target on shares of Repligen in a research report on Monday, July 6th. JPMorgan Chase & Co. raised their price target on shares of Repligen from $165.00 to $175.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. Finally, HSBC cut their price objective on shares of Repligen from $170.00 to $150.00 and set a "buy" rating on the stock in a research report on Wednesday, June 3rd. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Repligen has a consensus rating of "Buy" and a consensus target price of $166.43.

Repligen Profile

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source